ABANTE QUANT VALUE, F.I.

Enters the portfolio at 2.74% weight.

Montage Gold Corp. engages in the acquisition, exploration, and development of mineral properties in Africa. It explores for gold, nickel, cobalt, copper, lithium, tantalum, niobium, and beryllium deposits. The company's flagship property is the 90% owned Koné Gold project located in the Côte d'Ivoire, West Africa. Montage Gold Corp. was incorporated in 2019 and is headquartered in Vancouver, Canada.

Enters the portfolio at 2.45% weight.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

Enters the portfolio at 2.43% weight.

Omai Gold Mines Corp. engages in the acquisition, exploration, evaluation, and development of mineral properties. The company explores for gold and precious mineral deposits. It holds a 100% interests in the Omai prospecting license that covers an area of 4,590 acres located in the Potaro mining district of Guyana. The company is based in Toronto, Canada.

Enters the portfolio at 2.18% weight.

Teads Holding Co., together with its subsidiaries, operates a technology platform that connects media owners and advertisers with engaged audiences to drive business outcomes in the United States, Europe, the Middle East, Africa, and Asia. The company operates a two-sided marketplace, forming an end-to-end advertising platform with direct media owner and advertiser relationships. It also provides advertising solutions for advertisers, including a CPC performance platform and CPM-based managed and self-service platforms, and bespoke creative studio solutions that provide data-driven creative tailored to various environments and channels. In addition, the company offers budgets spanning video, display, native, native, vertical video, and other formats, as well as technology solutions that enable media owners to deeply engage their audiences, increasing the total revenue opportunity media owners can realize. Teads Holding Co. was formerly known as Outbrain Inc. and changed its name to Teads Holding Co. in June 2025. Teads Holding Co. was incorporated in 2006 and is headquartered in New York, New York.

Enters the portfolio at 2.14% weight.

Nippon Seiki Co., Ltd., together with its subsidiaries, engages in the manufacturing and selling automotive, motorcycle, and general-purpose instruments, consumer electronics instruments, resin materials, and automobiles in Japan, the Americas, Europe, and the rest of Asia. It operates through four segments: Automotive Parts Business, Consumer Parts Business, Resin Compound Business, and Automobile Sales Segment. The company provides instrument cluster, head-up displays; level, revolution, angle, stroke, inertial, and ultrasonic velocity sensors; automotive EMS with high-density PCB mounting for automotive components; and aftermarket products, such as link meters and multi-digital displays under the Defi brand; and plastic optics design and manufacturing services. It also offers household appliances, including remote controllers for air conditioners, water heaters, and central controller equipment; office automation equipment comprising operation panels for multi-functional printers; and factory automation equipment for remote terminals. In addition, the company sells new and used automobiles; and provides car inspection and repair services, as well as offers car rental services. Further, it engages in the process and sale of resin materials; manufactures speedometers and engine tachometers, building and household control circuits, assembling harnesses for in-vehicle instruments, and fuel gauge sender units; provision of logistics, import/ export customs clearance, food, insurance agency, and advertising agency services; and information systems and services, and software and UI consulting business. Nippon Seiki Co., Ltd. was incorporated in 1946 and is headquartered in Nagaoka, Japan.

Enters the portfolio at 1.83% weight.

Nakayama Steel Works, Ltd. engages in the steel, engineering, building materials, and real estate businesses in Japan. It offers steel coil products, including hot, pickled, plated, slit, and striped /pattern coils; and steel plate products, such as thick steel and NP steel plates, leveling sheets, checker plate, and pattern steel sheet, as well as hot rolled steel products. The company also provides bars and wire rod products comprising steel bars, burn-in- coils, and wire rods, as well as lightweight C-shaped steel, pipes, wire rod secondary products, steel billets, and by-products. In addition, it offers steel artificial reefs, breeding reefs, and floating artificial reef recovery; and casting machine engineering products, including rolls, valves, and casting and processing equipment. Further, it engages in manufacturing and processing of lightweight shaped steel sections, electric resistance welded steel pipes, and construction-related products; buying, leasing, brokerage, and sale of real estate properties; and port transportation and freight vehicle transportation businesses. The company provides general shipping and shipping brokerage services; and environmental services. The company was incorporated in 1923 and is headquartered in Osaka, Japan.

Enters the portfolio at 1.67% weight.

Nakano Corporation engages in the construction and real estate business in Japan, Singapore, Malaysia, Indonesia, Thailand, Vietnam, and internationally. The company provides design and construction of factories, large-scale condominiums, hotels, offices, data centers, production and logistics facilities, warehouses, and educational institutions; civil engineering services, including various roads, bridges, and rivers projects, as well as erosion control; and renovation work. It also engaged in real estate rental business; solar and wind power generation businesses; and insurance agency services. Nakano Corporation was founded in 1885 and is headquartered in Tokyo, Japan.

Enters the portfolio at 1.43% weight.

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Enters the portfolio at 1.40% weight.

Kitagawa Corporation manufactures and supplies synthetic metals, machine tool accessories, and industrial machinery in Japan and internationally. The company offers standard and advanced chucks, jaw force testers, manual chucks, rotary cylinders, chuck parts, NC rotary tables, power vises, work grippers, robot accessories, vise parts, and other peripheral equipment for machine tools such as turning centres and vertical machining centres. It also provides tower cranes for building construction, concrete mixing plants, multi-story car parking, and bridge erection machines, as well as recycling plants; and components for automotive industry. The company was formerly known as Kitagawa Iron Works Co., Ltd. and changed its name to Kitagawa Corporation in June 2018. Kitagawa Corporation was founded in 1918 and is headquartered in Fuchu, Japan.

Enters the portfolio at 1.28% weight.

Topre Corporation engages in the press-related products and temperature-controlled logistics-related businesses in Japan. The company offers press-related products; ultra-high-tensile steel plates and hot stamp pressed product; and constant temperature logistics products for light vehicles and heavy vehicles, as well as compact, 2t, 3t, and 4t trucks. It also provides home ventilation system; and electronic products, such as keyboards, pin pads, ouch monitor, touch panel, and embedded computer. In addition, the company offers automotive press components, office equipment parts, and press dies; and freezing containers, freezing equipment, freezers and refrigerators, and temperature-controlled logistics centers. The company was formerly known as Tokyo Press Kogyo Co., Ltd. and changed its name to Topre Corporation in October 1985. Topre Corporation was incorporated in 1935 and is headquartered in Tokyo, Japan.

Enters the portfolio at 1.23% weight.

Enters the portfolio at 1.10% weight.

XTI Aerospace, Inc., an aerospace company, provides unmanned aerial systems solutions for enterprise, public safety, government, and defense customers in the United States and Poland. The company offers enterprise drone distribution, training, compliance management support, repair and maintenance, fleet sustainment, and related services. It also provides TriFan 600, a fixed-wing aircraft design concept; distributes UAS platforms, payloads, sensors, batteries, accessories, and related equipment from third-party manufacturers; operate drone programs; lifecycle support services; fleet management tools, software integration, and operational workflow support services; and sales support and financing services. It serves customers across multiple end markets, including agriculture, construction, inspection, mining, insurance, security, and energy and utilities. XTI Aerospace, Inc. is headquartered in Addison, Texas.

Enters the portfolio at 1.09% weight.

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Enters the portfolio at 1.07% weight.

Rent the Runway, Inc. operates shared designer closet in the United States. The company provides evening wear and accessories, ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear under subscription, rental, and resale offering. It also engages in software development and support activities. The company was incorporated in 2009 and is headquartered in Brooklyn, New York.

Enters the portfolio at 1.04% weight.

Apollo Silver Corp. explores and develops silver properties in the United States, Canada, and Mexico. Its flagship project is the Calico Project that covers an area of 8,283 acres located in Mojave Desert of San Bernardino County, California. The company was formerly known as Apollo Gold & Silver Corp. and changed its name to Apollo Silver Corp. in September 2021. Apollo Silver Corp. was incorporated in 1999 and is headquartered in Vancouver, Canada.

Enters the portfolio at 1.02% weight.

LanzaTech Global, Inc. operates as a nature-based carbon refining company in North America, Europe, the Middle East, Africa, and Asia. It develops technology that transforms waste carbon into chemical building blocks for transportation fuels, household cleaners, packaging materials, fibers for clothing, and fragrances. The company's gas fermentation technology platform converts waste carbon gases into ethanol and its derivative products. It also provides techno-economic feasibility studies; basic engineering design services for commercial plants; and biotechnology research and development services for commercial and government entities. In addition, the company licenses and sells biocatalysts, such as microbes and media. Further, it provides fuel-grade ethanol under the CarbonSmart brand; and protein-rich byproducts, which are used as industrial protein, animal and fish feed, and fertilizers. LanzaTech Global, Inc. was founded in 2005 and is headquartered in Skokie, Illinois.

Enters the portfolio at 1.01% weight.

Soluna Holdings, Inc., together with its subsidiaries, engages in the mining of cryptocurrency through data centres. It operates through three segments, Cryptocurrency Mining, Data Center Hosting, and High-Performance Computing Services. The company also operates in the blockchain business, as well as provides colocation and hosting services to large-scale bitcoin mining operators. In addition, the company develops and builds modular data centrers that use for cryptocurrency mining. Further, it provides data center hosting services, including electrical power and network connectivity to cryptocurrency mining customers. Soluna Holdings, Inc. was formerly known as Mechanical Technology Inc and as changed to Soluna Holdings, Inc. in November 2021. The company was founded in 1961 and is headquartered in Albany, New York.

Enters the portfolio at 1.00% weight.

Hysan Development Company Limited is a leading property investment, management, and development company with a core portfolio of high-quality office, retail and residential space in Hong Kong. With roots in the city that go back more than 100 years, Hysan has focused on building the community, mixing the traditional and the new, applying technology and practicing sustainability. It has transformed the Lee Gardens area into a modern smart community, with a unique Hong Kong character, making it an attractive destination for leading multinational corporations, international visitors and residents. The Company has been growing its core portfolio through upgrades and expansion. It has also invested in strategic growth pillars which target opportunities brought about by the New Economy, with the aim of reinforcing Hysan's business by geography and by sector. Among its strategic pillars are Lee Gardens Shanghai and residential property development projects. Hysan Development Company Limited was incorporated in 1923 in Hong Kong.

Enters the portfolio at 0.99% weight.

Société Générale Société anonyme provides banking and financial services to individuals, corporates, and institutional clients in Europe and internationally. It operates through French Retail, Private Banking and Insurance; International Retail, Mobility and Leasing Services; and Global Banking and Investor Solutions. The company offers retail banking services, such as consumer credit, vehicle leasing and fleet management, online banking, wealth management, and equipment and vendor finance services; and insurance products, including home, vehicle, family, health, and mortgage insurance. It also provides corporate and investment banking, securities, clearing services, execution, prime brokerage, and custody services; and consumer finance, advisory and financing, and asset management and private banking services. Société Générale Société anonyme was incorporated in 1864 and is headquartered in Paris, France.

Enters the portfolio at 0.90% weight.

Tullow Oil plc, an energy company, develops, produces, and sells oil and gas resources in Ghana and Côte d'Ivoire. The company was founded in 1985 and is headquartered in London, the United Kingdom.

Enters the portfolio at 0.85% weight.

Singamas Container Holdings Limited an investment holding company, manufactures and sells containers and other related products. It operates in two segments, Manufacturing and Leasing; and Logistics Services. The Manufacturing and Leasing segment manufactures dry freight, collapsible flatrack, open top, tank, offshore, customised, energy storage system, data center, and other specialized containers; and container parts, as well as leasing of dry freight containers. The Logistics Services segment provides container storage, repair and drayage, trucking, container/cargo handling, and other container related services; and serves as a freight station. It operates container depots in Dalian, Tianjin, Qingdao, Shanghai, Ningbo, Fuzhou, and Xiamen ports. The company also provides container leasing, management, property holding, and human resource management services. It operates in the People's Republic of China, Hong Kong, and internationally. The company was incorporated in 1988 and is based in Wan Chai, Hong Kong.

Enters the portfolio at 0.79% weight.

Dragonfly Energy Holdings Corp. engages in the manufacturing and sale of deep cycle lithium-ion batteries for recreational vehicles, marine vessels, solar and off-grid residence industries, and industrial and energy storage markets. It operates in two segments, direct-to-consumers and original equipment manufacturers. The company provides lithium power systems comprising solar panels, chargers and inverters, system monitoring, alternator regulators, accessories, and others. It also offers battery management systems for monitoring and controlling of battery systems, and to protect battery cells from damage in various scenarios, as well as battery communication system. In addition, the company offers Dragonfly IntelLigence, a communication technology that unlocks real-time monitoring, instant notifications, protocol integration, and superior battery protection. The company provides its products under the Dragonfly Energy, Battle Born, and Wakespeed brand names. It serves recreational vehicle, heavy duty trucking, industrial solar integration, oil and gas, off grid residential, backup power, marine, and work truck industries. The company has a strategic partnership with Sphere Energy to develop and integrate AI capabilities into battery technologies and integrated power systems. Dragonfly Energy Holdings Corp. is headquartered in Reno, Nevada.

Enters the portfolio at 0.79% weight.

Atrium Mortgage Investment Corporation provides financing solutions to the residential, multi-residential, and commercial real estate businesses in Canada. It offers various types of mortgage loans, such as land and development financing, construction and mezzanine financing, commercial term and bridge financing services, and residential mortgages products. Atrium Mortgage Investment Corporation was incorporated in 2001 and is headquartered in Toronto, Canada.

Enters the portfolio at 0.78% weight.

Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.

Enters the portfolio at 0.77% weight.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Enters the portfolio at 0.75% weight.

First Juken Co., Ltd., together with its subsidiaries, engages in the construction and sale of single-family homes in Japan. It operates through Detached House Business; and Condominium Business, etc. segments. The company is also involved in the sale of renovated, refurbished, and second-hand condominiums; and provision of real estate rental services for condominiums and other properties. In addition, it engages in custom-built housing business; real estate sales, brokerage, placement, rental, and management; and non-life insurance agency and life insurance solicitation. Further, the company provides architectural and civil engineering design; construction supervision; construction; and consulting services. First Juken Co., Ltd. was incorporated in 1999 and is headquartered in Amagasaki, Japan.

Enters the portfolio at 0.70% weight.

Kamei Corporation operates as a general trading company in Japan and internationally. It provides LED lighting, eco pumps, and warm glasses; energy management-related products, such as solar power generation systems, lithium-ion storage batteries, etc.; chemical products comprising industrial chemicals, water treatment agents, alcohol, etc.; industrial materials and equipment consisting of logistics materials, compressors, generators, air-conditioning equipment, Karcher products, etc.; office supplies; ICT solutions and services; insurance products; and emergency earthquake warning systems, fire extinguishers, and fire-extinguishing equipment. The company also supplies automobile and industrial lubricants, oil products, LNG and LPG products, and home-use propane gas and kerosene; kitchen and hot water supply systems, as well as equipment; household fuel cells; manufactures, processes, and sells food products; and delivers alcoholic beverages, soft drinks, food products, restaurant ingredients, and processing ingredients; and engages in directly run supermarkets and restaurant businesses. In addition, it operates a network of service stations that offer refueling services, as well as car wash, tire and oil change, safety and vehicle inspection, coating, and other maintenance services; provides automobile leasing services; and undertakes steel frame, exterior cladding, and metal siding construction works. Further, the company operates pharmacies; and offers renovation services. It operates 269 gas stations, 34 oil depots, 15 gas terminals, 4 automobile LPG stations, 2 food distribution centers, 111 pharmacies, and 1 supermarket. The company was formerly known as Kamei Shoten Co. and changed its name to Kamei Corporation in 1985. Kamei Corporation was founded in 1903 and is headquartered in Sendai, Japan.

Enters the portfolio at 0.66% weight.

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Enters the portfolio at 0.63% weight.

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Enters the portfolio at 0.59% weight.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Enters the portfolio at 0.58% weight.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Enters the portfolio at 0.48% weight.

T.RAD Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, and sale of heat exchangers for automobiles, construction and industrial machines, air conditioners, generators, and others in Japan, the United States, China, rest of Asia, and internationally. The company offers radiators, oil and EGR coolers, charge air coolers, fin coils for air conditioners, and other heat exchangers. It also engages in the research, development, manufacture, and sale of environment-related equipment; and provision of solutions utilizing thermal energy conversion technology and information technology. The company was formerly known as Toyo Radiator Co., Ltd. and changed its name to T.RAD Co., Ltd. in April 2005. T.RAD Co., Ltd. was incorporated in 1936 and is headquartered in Shibuya, Japan.

Enters the portfolio at 0.47% weight.

CPBIO Holding Company Limited manufactures and sells animal health products and chlortetracycline in Mainland China, the Asia Pacific, the Americas, Europe, and internationally. It operates through two segments: Biotech Business and Investment Business. The Biochemical segment is engaged in the manufacture and/or sale of animal health products and chlortetracycline, which are used as feed additives to promote growth of livestock, prevent or cure animal diseases, and enhance efficiency under the Shihao and Citifac brand names. The company offers products such as gut & health enhancement, antibioticsanticoc & antiparasitics, bioprotection, detection kits, enzyme, plant extracts, vaccine, and trade. The company also provides solution for poultry, swine, ruminants, and aquaculture. The Investment segment is engaged in the trading of machinery and the manufacture and sale of automotive parts; and caterpillar products, including excavators, power generators, bulldozers and compactors, as well as spare parts; and the manufacture and sale of motorcycle carburetors. The company serves livestock farms, pharmaceutical companies, trading companies, feed mills, automobile manufacturers, and motorcycle manufacturers. CPBIO Holding Company Limited was formerly known as Chia Tai Enterprises International Limited and changed its name to CPBIO Holding Company Limited in July 2026. CPBIO Holding Company Limited was incorporated in 1987 and is based in Central, Hong Kong.

Enters the portfolio at 0.46% weight.

Okaya Electric Industries Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of electrical components and equipment in Japan, Hong Kong, Thailand, China, North America, and internationally. The company offers noise suppression products, such as noise suppression capacitors, spark killers, high pulse capacitors, noise filters, and common mode choke coils; surge protective devices (SPD), including module, PCB mounted, and SMD type SPD; LED display devices and lighting source products; and sensor products. Its products are used in air conditioner, refrigerators, cooking appliances, audiovisual and communication equipment, medical equipment, industrial equipment, and urban infrastructure. The company was formerly known as Okaya Radio Co., Ltd. and changed its name to Okaya Electric Industries Co., Ltd. in 1967. Okaya Electric Industries Co., Ltd. was incorporated in 1939 and is headquartered in Setagaya, Japan.

Enters the portfolio at 0.45% weight.

JK Holdings Co., Ltd., together with its subsidiaries, engages in the wholesale of decorative plywood, building materials, and housing equipment in Japan and internationally. It operates through three segments: General Building Materials Wholesale; General Building Materials Retail; and Plywood Manufacturing and Wood Processing. The company manufactures and sells ordinary, secondary, structural, and long plywood; plywood-based products; veneer; laminated veneer, timber, and lumber; laminated processed products; wood products; logs; building materials; and home appliances. It also provides structural design, supply of wooden structural frames, pre-cutting, construction, material supply for wooden interior, and installation. In addition, the company is involved in construction work; warehousing and transportation; general cargo; material brokerage; real estate rental; franchise business; travel and insurance agency; housing loan; and e-commerce and management. The company exports its products. JK Holdings Co., Ltd. was founded in 1937 and is headquartered in koto, Japan.

Enters the portfolio at 0.44% weight.

Nakabayashi Co., Ltd engages in the business process solution, consumer-communication, office appliance, energy, and other businesses in Japan and internationally. The company operates through Business Process Solutions Business, Consumer Communications Business, and Energy Business segments. The Business Process Solutions Business segment offers BPO services, such as printing, data printing, bookbinding, library, building solutions, and manufacturing and sales of notebooks, as well as staffing services. The Consumer Communications Business segment offers notebooks, albums, files, storage and organization supplies, gadget accessories, printer paper, child seats, shredders, bookbinding machines, electronic medical record carts, IV stands, and others. It also sells office furniture, wooden furniture, and recycles wastepaper. The Energy Business segment offers wood biomass power generation and solar power generation. The company offers shredder, note tool, PC peripheral equipment, smartphone, silver, the game relation, digital camera relate, office supplies, digital stationery, stuffed animal and child seat, character series products, store and arrangement, document scanning, and disaster prevention security. Nakabayashi Co., Ltd. was formerly known as Nakabayashi Bookbinding and Printing Co., Ltd. and changed its name to Nakabayashi Co., Ltd. in October 1970. Nakabayashi Co., Ltd. was founded in 1923 and is headquartered in Osaka, Japan.

Enters the portfolio at 0.44% weight.

Seiwa Electric Mfg. Co., Ltd., together with its subsidiaries, manufactures and sells information equipment, lighting equipment, and components in Japan and internationally. The company offers information display systems for roadways, parking, and waterway conditions; emergency information systems for tunnels; monitoring boards for industrial plants; traffic control systems; and LED information displays. It also provides lighting and control equipment, including LED road lighting fittings, explosion proof type LED lighting fittings, and explosion proof type control boxes; and wire protection devices, such as e-Duct, a polyvinyl chloride-free protective cable housing. In addition, the company offers EMC products comprising fingers, gaskets, surface mounting fingers and gaskets, nonwoven fabric gaskets, ferrite cores, conductive cloth tapes, shield tubes, grounding straps and clamps, electromagnetic wave control sheets, conductive silicone rubbers, metal foil tapes and sheets, thermal conductive sheets, radiation and heat shielding paints, and magnetic field probes. Further, it is involved in the manufacturing and sale of electromagnetic environment protection parts; irregularly shaped extrusion molded products; and computer software, as well as maintenance services. The company was founded in 1945 and is headquartered in Joyo, Japan.

Enters the portfolio at 0.43% weight.

Trinseo PLC provides specialty material solutions in the United States, Europe, the Asia-Pacific, and internationally. The company operates through four segments: Engineered Materials, Latex Binders, Polymer Solutions, and Americas Styrenics. The Engineered Materials segment offers rigid thermoplastic compounds and blends, soft thermoplastic elastomers, activated methyl methacrylates, and polymethyl methacrylates resins for consumer electronics, medical, footwear, automotive, wellness, and building and construction applications under the EMERGE, CALIBRE, PLEXIGLAS, ALTUGLAS, PULSE, ACRYSPA, AVONITE, STUDIO, MEGOL, APILON, APIGO, and APINAT trade names. The Latex Binders segment provides various latex binder products, including styrene-butadiene latex, styrene-acrylate latex, vinylidene chloride latex, all-acrylic latex, and butadiene-methacrylate latex for coatings, adhesives, sealants, and elastomers applications. The Polymer Solutions Segment offers a range of polymers, such as copolymers, polycarbonate, styrene-acrylonitrile, and acrylonitrile-butadiene-styrene under the MAGNUM, CALIBRE, and STYRON brand used in automotive, appliances, consumer goods, and construction sheet applications. The Americas Styrenics segment provides styrene monomer, polystyrene, general purpose polystyrenes, high heat and impact resins, and STYRON A-TECH polystyrene products for appliances, food packaging, food service disposables, consumer electronics, and building and construction materials applications. Trinseo PLC was incorporated in 2015 and is based in Wayne, Pennsylvania. On May 26, 2026, Trinseo PLC, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Enters the portfolio at 0.42% weight.

Sakai Chemical Industry Co., Ltd., together with its subsidiaries, manufactures and sells chemical industrial products in Japan, Asia, North America, Europe, the Middle East, and internationally. The company offers barium and strontium salt products; and zinc oxide for rubber, paints, plastics, electronic materials, cosmetics, and heat-dissipation materials. It also provides plastic additives, such as metallic soaps, hydrotalcite, and flame retardants, as well as calcium/zinc-based composite stabilizers; catalysts comprising De-NOx/De-DXN catalysts, hydrogenation catalysts, titanium catalysts for polyester polymerization, titanium dioxide for catalyst carriers, and catalysts for raw materials of synthetic fibers; and electronic materials, which includes dielectric materials, spherical silica, and secondary batteries and electrode materials. In addition, the company offers cosmetic raw materials, such as titanium dioxide, flake-shaped barium sulfate, spherical calcium carbonate, spherical barium sulfate, and cosmetic inorganic fluorescent materials. Further, it provides organic chemical products containing sulfur and phosphorus structures for the electronics, resin materials, pharmaceuticals and healthcare, lubricant materials, and water treatment materials sectors; pharmaceuticals comprising prescription and OTC drugs, health food, active pharmaceutical ingredients, and pharmaceutical intermediates; and road marking materials for compartment lines, road markings, expressways, and braille sheets. The company exports its products. Sakai Chemical Industry Co., Ltd. was founded in 1918 and is headquartered in Sakai, Japan.

Enters the portfolio at 0.41% weight.

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.

Enters the portfolio at 0.41% weight.

LivePerson, Inc. operates as a digital customer conversation in the United States, Canada, Latin America, South America, Europe, the Middle East, Africa, and the Asia-Pacific. It enables brands to leverage the LivePerson Platform's intelligence engine to connect with consumers through an integrated suite of mobile and online business messaging technologies. The company offers the LivePerson Platform, an enterprise-class digital customer conversation platform, which enables businesses and consumers to connect through conversational channels, such as voice, in-app, and mobile messaging. It also provides professional services; LivePerson's Conversational AI, including conversation builder, manager, and intelligence, and intent manager. In addition, the company offers cloud-based suite of messaging, real-time chat, Generative AI, AI and automation, and conversation orchestration comprising LLM powered automation tools; LLM powered agent tools; conversation intelligence tools; integrations; and engagement solutions. Further, it offers Syntrix platform that enables enterprises to test, evaluate, and validate AI behavior by identifying drift and failures before they reach real customers; and hosted service. The company serves telecommunications, financial services, travel and hospitality, technology, healthcare, automotive, and consumer and retail businesses. LivePerson, Inc. was incorporated in 1995 and is headquartered in New York, New York. As of September 4, 2026, LivePerson, Inc. operates as a subsidiary of SoundHound AI, Inc.

Enters the portfolio at 0.41% weight.

VSee Health, Inc. provides telehealth care solutions in the United States. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions. It also provides telehealth software building blocks, such as patient engagement, clinician staffing, remote physical exam and remote patient monitoring, and AI for telesitter and telenursing solutions; data connectors; and workflow templates. The company distributes its products through third-party resellers and affiliated hospitals, as well as sales executives. The company is headquartered in Newton, Massachusetts.

Enters the portfolio at 0.40% weight.

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.

Enters the portfolio at 0.38% weight.

Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Enters the portfolio at 0.37% weight.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.

Enters the portfolio at 0.34% weight.

Maxeon Solar Technologies, Ltd., a marketers of solar power technology, designs, manufactures, markets, and sells solar panels for residential, commercial, and power plant customers. The company was incorporated in 2019 and is headquartered in Singapore. Maxeon Solar Technologies, Ltd. operates as a subsidiary of TCL Zhonghuan Renewable Energy Technology Co.,Ltd.

Enters the portfolio at 0.33% weight.

Mobix Labs, Inc. designs, develops, and sells components and systems for advanced wireless and wired connectivity, radio frequency (RF), and switching and electromagnetic interference (EMI) filtering technologies in the United States, and internationally. The company's wireless systems solutions include products for advanced RF and millimeter wave (mmWave) 5G communications, mmWave imaging, software defined radio, and custom RF integrated circuits; interconnect products comprise EMI filter inserts and filtered and non-filtered connectors. Its products are used in the consumer commercial, industrial, automotive, medical, aerospace, military, defense, and other markets. The company is based in Irvine, California.

Enters the portfolio at 0.31% weight.

Emperor Watch & Jewellery Limited, an investment holding company, engages in the sale of watches and jewelry products. It is involved in retailing European-made watches and jewelry products under the Emperor Jewellery brand name; and property investment activities. The company also offers jewelry products, including rings, necklaces, pendants, bangles, bracelets, earrings, and charms, as well as bridal jewelry products. The company sells its products through self-branded stores, watch boutiques, and multi-brand watch stores, as well as through an online shopping platform. It has operations in Hong Kong, Macau, Chinese Mainland, Singapore, and Malaysia. Emperor Watch & Jewellery Limited was founded in 1942 and is based in Wan Chai, Hong Kong. The company operates as a subsidiary of Emperor Watch & Jewellery Group Holdings Limited.

Enters the portfolio at 0.30% weight.

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

Enters the portfolio at 0.30% weight.

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, China, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. It operates through Dermatology Recurring Procedures and Dermatology Procedures Equipment segments. The company offers XTRAC excimer laser and VTRAC lamp systems, which are used in the treatment of psoriasis, vitiligo, atopic dermatitis, and leukoderma; and TheraClear acne therapy system for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. It serves dermatologists and dermatological group clinics. The company was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015. STRATA Skin Sciences, Inc. was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.

Enters the portfolio at 0.29% weight.

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Enters the portfolio at 0.29% weight.

China Starch Holdings Limited, an investment holding company, manufactures and sells cornstarch, lysine, starch-based sweeteners, modified starch, and ancillary corn-based and corn-refined products in the People's Republic of China. The company operates through two segments, Upstream Products, and Fermented and Downstream Products. It also researches, develops, manufactures, and sells, cornstarch, glucose, maltose, dextrin, animal feed additives, food-grade enzymes, biobased materials, amino acids, lactate acid esters, and related products. The company was incorporated in 2006 and is headquartered in Wan Chai, Hong Kong. China Starch Holdings Limited is a subsidiary of Merry Boom Group Limited.

Enters the portfolio at 0.28% weight.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

Enters the portfolio at 0.27% weight.

Enters the portfolio at 0.26% weight.

Peraso Inc., a fabless semiconductor company, develops, markets, and sells semiconductor devices and antenna modules in Europe, North America, Hong Kong, Taiwan, and internationally. The company offers millimeter wavelength (mmWave) integrated circuits (ICs), including baseband IC, various variations of mmWave radio frequency, ICs, and associated antenna technology; and mmWave antenna modules for license-free 60 gigahertz (GHz) applications. Its mmWave products are used for various applications comprising multi-gigabit point-to-point wireless links with a range of up to 25 kilometers and operating in the 60 GHz frequency band; multi-gigabit point-to-multi-point links in the 60 GHz frequency band used to provide fixed wireless access (FWA) services; FWA in the 5G operating bands from 24 GHz to 43 GHz to provide multi-gigabit capability and low latency connections; military communications; and consumer applications, such as high performance wireless video streaming, and untethered augmented reality and virtual reality. The company also provides memory products, such as bandwidth engine ICs, which are memory-dominated ICs for high-speed cloud networking, communications, security appliance, video, monitor and test, data center and computing markets that deliver time-to-market, performance, power, area to system original equipment manufacturers. In addition, it licenses intellectual property and offers non-recurring engineering services. The company sells and markets its products through direct sales personnel and sells to representatives and distributors. Peraso Inc. was founded in 1991 and is headquartered in San Jose, California.

Enters the portfolio at 0.25% weight.

Yoshicon Co.,Ltd. engages in the buying, sale, intermediation, leasing, management, and research of real estate properties in Japan. It also sells patent, utility model, design, and trust beneficiary rights; and construction and environmental materials. In addition, the company is involved in investment advisory; sale of electricity; and operation and management of parking lots and solar power plants, as well as attraction of commercial facility factories. Yoshicon Co.,Ltd. was founded in 1949 and is headquartered in Shizuoka, Japan.

Enters the portfolio at 0.24% weight.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Enters the portfolio at 0.23% weight.

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Enters the portfolio at 0.23% weight.

Sky Quarry Inc. operates as an oil production, refining, and development-stage environmental remediation company in the United States. It facilitates the recycling of waste asphalt shingles and remediation of oil-saturated sands and soils. The company also refines heavy crude oil to produce diesel and other petroleum products, such as paving asphalt liquids, vacuum gas oil, and naphtha. In addition, it holds 100% interest in asphalt bitumen leases covering approximately 5,930 acres in the PR Spring region in Utah. The company was formerly known as Recoteq Inc. and changed its name to Sky Quarry Inc. in April 2020. Sky Quarry Inc. was incorporated in 2019 and is headquartered in Woods Cross, Utah.

Enters the portfolio at 0.22% weight.

Big Digital Energy, Inc., a technology company, designs, develops, and operates digital infrastructure platforms in the United States. The company offers artificial intelligence and high-performance computing; digital asset colocation; and technology and information systems. The company was formerly known as Mawson Infrastructure Group Inc. and changed its name to Big Digital Energy, Inc. in April 2026. Big Digital Energy, Inc. is based in Midland, Pennsylvania.

Enters the portfolio at 0.20% weight.

Leslie's, Inc. operates as a direct-to-consumer pool and spa care brand in the United States. The company markets and sells pool and spa supplies and related products and services. It also offers various pool and spa maintenance items, such as chemicals, equipment and parts, and cleaning accessories, as well as safety, recreational, and fitness related products. In addition, the company provides installation and repair services for pool and spa equipment. Further, it offers complimentary, commercial grade water testing, and in-store equipment repair services. The company serves residential, professional, and commercial consumers through e-commerce websites and third-party marketplaces. Leslie's, Inc. was founded in 1963 and is headquartered in Phoenix, Arizona.

Enters the portfolio at 0.18% weight.

ESS Tech, Inc., an energy storage company, engages in the design and production of iron flow batteries for commercial and utility-scale energy storage applications worldwide. It offers energy storage products, which include Energy Warehouse, a behind-the-meter solution; and the gigawatt-hour energy base storage product, a fully configurable layout that integrates with any site location and that allows the power to be decoupled from the capacity. The company was founded in 2011 and is headquartered in Wilsonville, Oregon.

Enters the portfolio at 0.17% weight.

Solidion Technology, Inc., a battery technology company that focuses on the development and commercialization of battery materials, components, cells, and selected module/pack technologies. It provides advanced anode materials, silicon-rich all-solid-state lithium-ion cells, anode less lithium metal cells, and lithium-sulfur cells. The company also offers graphene or elastomer enhanced silicon, and SiOx, a silicon oxide anode; biochar-based anode; and electrolytes. The company was founded in 2015 and is headquartered in Dallas, Texas.

Enters the portfolio at 0.17% weight.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

Enters the portfolio at 0.16% weight.

Corvex, Inc., an AI cloud computing company, provides GPU-accelerated infrastructure for AI workloads to customers worldwide. The company provides graphics processing unit accelerated compute, confidential computing, token factory, and inference services purpose-built to protect and perform. It also offers an artificial intelligence cloud computing services specializing in graphics processing unit accelerated infrastructure for AI workloads. The company is based in Arlington, Virginia.

Enters the portfolio at 0.16% weight.

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Enters the portfolio at 0.15% weight.

SenesTech, Inc. engages in the development and commercialization of a technology for managing animal pest populations through fertility control. The company offers ContraPest, a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide; and Evolve, a soft bait containing the active ingredient, cottonseed oil that limits the reproduction of male and female rats beginning with the first breeding cycles following consumption. It also develops Evolve Mouse, a modified version of its bait technology containing the active ingredient cottonseed oil that limits reproduction of male and female mice. The company was incorporated in 2004 and is headquartered in Surprise, Arizona.

Enters the portfolio at 0.15% weight.

Healthcare Triangle, Inc., a healthcare information technology company, focuses on advancing solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record, and healthcare and life sciences industry. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to evidence, and accelerate their digital transformation. The company's software platforms include CloudEz, an enterprise multi-cloud transformation and management platform that enables customers to manage their cloud infrastructure in private, hybrid, and public cloud infrastructures; DataEz, a cloud-based data analytics and data science platform for the data analytics and data science requirements of life sciences/pharmaceutical and healthcare provider organizations; Blockchain infrastructure; and Cybersecurity navigator. It also provides Readabl.AI, a Software-as-a-Service solution that uses public cloud artificial intelligence and machine learning to recognize and extract healthcare information from documents, faxes, and narrative reports. In addition, the company offers cloud IT services; and healthcare IT services, such as electronic health records and software implementation, optimization, and extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. It also serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers. Healthcare Triangle, Inc. was incorporated in 2019 and is based in Pleasanton, California.

Enters the portfolio at 0.15% weight.

SmartKem, Inc., together with its subsidiaries, develops and sells transistors using its proprietary semiconductor materials. It offers TRUFLEX materials used in a range of applications, including MicroLED, LCD, and AMOLED displays, as well as computer and AI chip packaging and sensors. The company also develops the MiP4 and an all-organic-transistor biometric sensor. In addition, it provides prototyping services. The company was incorporated in 2009 and is headquartered in Manchester, the United Kingdom.

Enters the portfolio at 0.12% weight.

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Enters the portfolio at 0.10% weight.

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was founded in 2018 and is headquartered in Cincinnati, Ohio.

Enters the portfolio at 0.09% weight.

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. It also develops REQORSA Gene Therapy in Mesothelioma, Ras Inhibitor Resistant NSCLC, other tumor suppressor genes, and Glioblastoma, which is in preclinical studies. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive; New York University; UTHealth Houston; and University of Pittsburgh. The company also has a sponsored research agreement with The University of Texas MD Anderson Cancer Center to study biomarkers that for the prediction of patient response to Reqorsa Gene Therapy. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

Enters the portfolio at 0.09% weight.

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Enters the portfolio at 0.08% weight.

Capstone Holding Corp., through its subsidiaries, engages in the distribution and installation of building products in the United States and Canada. It operates in two segments, TotalStone and Carolina Stone. The company offers manufactured stone veneer under the Cultured Stone, Dutch Quality Stone, and Toro Stone brand names; natural stone under the Pangaea Stone brand name; panelized stone system under the Interloc brand name; mechanically attached stone veneer systems under the Beon Stone brand name; moisture management system under the D-Rain brand name; landscape and hardscape products under the Aura Natural Landscapes brand name; and modular masonry fireplaces under the Isokern brand name. It serves masonry dealers, brick distributors, landscape yards, hearth and home dealers, building material dealers, contractors, builders, and homeowners. The company was formerly known as Capstone Therapeutics Corp. and changed its name to Capstone Holding Corp. in February 2022. Capstone Holding Corp. was incorporated in 1987 and is headquartered in Alsip, Illinois.

Enters the portfolio at 0.08% weight.

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Enters the portfolio at 0.07% weight.

TEN Holdings, Inc. provides event planning, production, and broadcasting services in the United States. The company organizes virtual, hybrid, self-service, and physical events, including conferences, marketing events, product launches, trainings, and investors and shareholder meetings. Its events are enabled by its Xyvid Pro and TEN Pro platforms, which are internet-based broadcast platforms with interactive engagement tools designed to provide web broadcast audiences with a dynamic, interactive, and engaging virtual event experience. The company also provides live streaming and video recording for physical events; video editing and production; and a custom on-demand video library for finished video content to be viewed and downloaded. It serves a range of industries, such as technology firms, healthcare organizations, educational institutions, and marketing and advertising agencies, as well as nonprofits and associations. The company was formerly known as The Events Network, Inc. and changed its name to TEN Holdings, Inc. in June 2024. The company was founded in 2011 and is headquartered in Langhorne, Pennsylvania.

Enters the portfolio at 0.06% weight.

Interactive Strength Inc., together with its subsidiaries, develops and sells specialty fitness equipment and virtual training for the commercial and at-home markets in the United States, Europe, and Asia. The company offers vertical climbing equipment and a digital training platform under the CLMBR brand; indoor bikes that set the global standard in cycling under the Wattbike brand name; and hardware and digital fitness services under the FORME brand. It also provides Forme Studio, a fitness mirror; and Forme Studio Lift, a fitness mirror and cable-based digital resistance. Interactive Strength Inc. was incorporated in 2017 and is headquartered in Austin, Texas.

Enters the portfolio at 0.05% weight.

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.

Enters the portfolio at 0.05% weight.

Goes from 2.49% to 3.53%.

Standard Chartered PLC, together with its subsidiaries, provides various banking products and services in Asia, Africa, the Middle East, Europe, and the Americas. The company operates in three segments: Corporate & Investment Banking, Wealth & Retail Banking, and Ventures. It offers retail products, such as deposits, mortgages, credit cards, and personal loans; wealth management products and services that include investments, portfolio management, bancassurance, and wealth advice; and transaction banking services, such as cash management, working capital, trade financing, securities and prime services, and payments and liquidity products. The company also provides mergers and acquisitions, leveraged and acquisition finance, infrastructure and development finance, fund finance, and transportation and sustainable finance solutions. In addition, it offers international banking, private banking, priority banking, wealth solutions, financing for SMEs, and Islamic banking products. Further, the company provides financial markets products and services that comprise financing and investment ideas; risk management and investment solutions; foreign exchange, rates, credit, and structured products; capital raising solutions; and sales and structuring, as well as digital banking solutions. It serves financial institutions, governments, banks, investors, corporations, small to medium-sized businesses, and individuals. Standard Chartered PLC was founded in 1853 and is headquartered in London, the United Kingdom.

Goes from 1.87% to 2.54%.

NN Group N.V., a financial services company, provides life and non-life insurance products in the Netherlands and internationally. It operates through the Netherlands Life, the Netherlands Non-Life, Insurance Europe, Japan Life, and NN Bank segments. The company provides insured defined benefit, defined contribution, pensions under the Nationale-Nederlanden brand name; premium pension institution services under the BeFrank brand name; and general pension fund administration and advisory services under AZL brand name, as well as non-life insurance products, including motor, fire, liability, transport, travel, health, and disability and accident insurance products. It also provides long-term protection to cover a variety of risks including disability, critical illness and health; and protection, savings and retirement solutions. In addition, the company offers financial services, such as savings, investments, bancassurance and mortgages under the Woonnu brand name. The company offers its products to individuals, small and medium-sized enterprises, and corporate customers directly through tied agents, advisors, brokers, and direct channels. The company was formerly known as ING Insurance Topholding N.V. and changed its name to NN Group N.V. in March 2014. NN Group N.V. was founded in 1845 and is headquartered in The Hague, the Netherlands.

Goes from 2.92% to 3.42%.

Banco BPM S.p.A. provides banking and financial products and services to individual, business, and corporate customers in Italy. The company operates through six segments: Commercial; Corporate and Investment Banking; Asset Management and Insurance; Other Partnerships; Finance; and Corporate Centre. It offers current account and digital services; safety deposit boxes; home, personal, property, and car and vehicle insurances; credit, telepass family, debit, payment, and prepaid cards; T3 Trading, web, and T3 mobile platforms; home and surrogacy mortgagees; long term car rental; personal loans, including salary-backed loan; calculate mortgage payments; mutual funds, insurance investment, saving, and certificate products; and supplementary pension securities comprising true life secure retirement and anima arts and crafts pension funds. The company also provides business current accounts; green and sustainable, ordinary financing, dedicated, subsidized, and condominium credit financing products; international payments and collections, trade and export finance, and digital international solutions; license plate, equipment, real estate, renewable energy, operating, and nautical leasing services; POS receipts; and RIBA, MAV and SDD collections. In addition, it offers multi-risk, personal, property, and motor vehicle insurance; corporate cards; digital services; foreign risk coverage, exchange risk hedging, and interest rate risk coverage; investment banking, including equity capital market, mergers and acquisitions, securitization, and debt capital markets; documentary box office receipts, electronic collections abroad, international guarantees, and pro-soluto assignment of export credits services; structured finances; and collection and payment services. The company was formerly known as Banco Popolare Societa Cooperativa Scarl and changed its name to Banco BPM Società per Azioni in January 2017. Banco BPM S.p.A. was founded in 2017 and is headquartered in Verona, Italy.

Goes from 1.03% to 1.29%.

Sanyo Chemical Industries, Ltd. manufactures and sells chemical products in Japan. It offers multiple specialty categories, including extracellular vesicle purification kits, plant-derived textiles, fluidity improvers, nonionic surfactants, polyurethane materials, anionic surfactants, and antimicrobial agents, lubricants, polypropylene glycol derivatives, nonionic surfactants, dispersants, rust inhibitors, nonionic surfactants for cleaning applications, sizing agents, aminoalkyl methacrylate monomers, tooling boards, and antistatic agents, plastic additives, functional chemicals, pressure sensitive adhesives, UV curing resins, and cosmetic raw materials. The company is also involved in warehousing services. It serves car, housing, cosmetics, electronic and semiconductors, medical and life style industries. The company was formerly known as Sanyo Chemical Industry Co. and changed its name to Sanyo Chemical Industries, Ltd. in 1966. Sanyo Chemical Industries, Ltd. was incorporated in 1949 and is headquartered in Kyoto, Japan.

Goes from 1.34% to 1.57%.

Unipol Assicurazioni S.p.A., together with its subsidiaries, provides insurance products and services primarily in Italy. The company operates through Non-Life Insurance Business, Life Insurance Business, Banking Associates Business, and Other Business segments. It offers risk cover solutions for vehicles, sports craft, and travel; home and condominiums; work related to businesses, traders, professionals, and legal protection; accident and health protection; and investments and welfare. The company also provides life insurance products; bancassurance; and reinsurance services. In addition, it is involved in the operation and management of real estate properties; operation of hotels, residences, and resorts through leases, franchises, and management; agricultural, wine, healthcare facilities, and port facilities; and supplies of anti-theft systems, as well as provision of vehicle and glass repair services; mobile payments, telematics, and response services to assistance request; and telemedicine, home care and prevention, physiotherapy, and social care services. Further, the company offers digital health platform; property services to homes and condominiums, and administrators and owners; and electronic payment and e-money services. It distributes its products through direct sales; broker; agency, banking, and craftsmen network; and franchise administrators. The company was formerly known as Unipol Gruppo S.p.A. and changed its name to Unipol Assicurazioni S.p.A. in January 2025. Unipol Assicurazioni S.p.A. was founded in 1961 and is based in Bologna, Italy.

Goes from 3.28% to 3.49%.

NatWest Group plc, together with its subsidiaries, provides banking and financial products and services in the United Kingdom and internationally. It operates through the Retail Banking, Private Banking, and Commercial & Institutional segments. The Retail Banking segment offers a range of banking products and related financial services, such as current accounts, mortgages, personal unsecured lending, and personal deposits, as well as mobile and online banking services. Its Private Banking segment provides banking, lending, and wealth management products for high-net-worth individuals and their business interests. The Commercial & Institutional segment consists of customer businesses under business banking, commercial mid-market, and corporates and institutions; and offers banking operations services in the Channel Islands, Isle of Man, Gibraltar, and Luxembourg, as well as products and solutions for businesses comprising start-ups, corporates, and large institutions. The company was formerly known as The Royal Bank of Scotland Group plc and changed its name to NatWest Group plc in July 2020. NatWest Group plc was founded in 1727 and is headquartered in Edinburgh, the United Kingdom.